Special Patient Population Recruitment Tool for Global Drug Development
COSTA MESA, Calif., February 25, 2013/PRWeb/–WCCT Global, a contract research organization (CRO) supporting Phase I – IV biopharmaceutical and medical device development, announces today the roll-out of their innovative special population Recruitment Management Tool (RMT) for early and late phase clinical studies and global drug development. Recruiting the right participants into a clinical trial is a fundamental and essential element for success that easily gets overlooked. WCCT Global has built a cutting edge recruitment tool in order to meet the needs of sponsors who have studies either competitively or non-competitively recruiting in any region of the country.
The WCCT Global RMT consists of a proprietary algorithm which combines multiple web technologies which enables recruiters to target specific patients needed for any project. Any geographic region or diagnostic category can be targeted. The recruiters can be centrally located while recruiting nationally, thus, expending fewer resources and reducing overall recruitment times. WCCT is likely to save sponsors anywhere between 15 and 20 percent in costs not only because of their advanced patient recruitment strategy, but because of their combined clinical trial project, data, and site management expertise.
Lee Barsky, Vice President of Program Management said, “I truly believe our new special population recruitment tool is raising the bar for all Contract Research Organizations’ recruitment efforts. We are now able to precisely target the required resources to recruit specific patient populations anywhere in the US in record time.” WCCT Global has been able to successfully screen and randomize multiple special population clinical studies including Asian-bridging studies, difficult asthma studies, ophthalmology studies, and infectious disease studies using this recruitment management tool and feels it is a must have for every clinical trial. WCCT looks forward to using their special population recruitment strategy for rare diseases and indications, in order to advance global drug development for these very rare and difficult to treat conditions. It is in this way that the CRO’s special population recruitment methods can contribute to a much larger mission of drug development for patient populations that need more effective treatments the most.